DISCOUNT ZERTIFIKAT - ASTRAZENECA | Market Closed - Bid/Ask 16:20:33 03/06/2024 BST | ||
| 121.5 EUR | +0.86% |
|
| 1 month | +0.63% | ||
| 3 months | +11.40% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 03/06/24 | 121.5 | +0.86% |
| 31/05/24 | 120.5 | +0.27% |
| 30/05/24 | 120.2 | +0.48% |
| 29/05/24 | 119.6 | -0.36% |
| 28/05/24 | 120 | -0.87% |
Real-time Boerse Frankfurt Warrants
Last update June 03, 2024 at 04:20 pm
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
BNP Paribas
|
| WKN | PC3VZU |
| ISIN | DE000PC3VZU3 |
| Date issued | 25/01/2024 |
| Maturity | 19/12/2025 (564 Days) |
| Parity | 1 : 1 |
| Emission price | 108.3 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 121.5 € |
|---|---|
| Lowest since issue | 103.1 € |
| Spread | 0.1 € |
| Spread % | 0.08% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
155.1
USD
Average target price
172
USD
Spread / Average Target
+10.91%
- Stock Market
- Certificates
- Certificat